GT200600116A - Derivados de aril 1,4-pirazina sustituidos - Google Patents
Derivados de aril 1,4-pirazina sustituidosInfo
- Publication number
- GT200600116A GT200600116A GT200600116A GT200600116A GT200600116A GT 200600116 A GT200600116 A GT 200600116A GT 200600116 A GT200600116 A GT 200600116A GT 200600116 A GT200600116 A GT 200600116A GT 200600116 A GT200600116 A GT 200600116A
- Authority
- GT
- Guatemala
- Prior art keywords
- pirazina
- aril
- derivatives
- substituted
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000013200 Stress disease Diseases 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Hospice & Palliative Care (AREA)
- Virology (AREA)
- Psychology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Anesthesiology (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
Abstract
LA PRESENTE INVENCIÓN SE REFIERE A COMPUESTOS DE LA FÓRMULA GENERAL I EN LA QUE R1,R2,R3,R4,R22, SON GRUPOS FUNCIONALES DESCRITOS EN EL EXPEDIENTE. ESTOS COMPUESTOS SON ANTAGONISTAS DEL RECEPTOR CFR POR LO QUE SON DE UTILIDAD EN TRASTORNOS DE ANSIEDAD, DEPRESIÓN Y ESTRÉS.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66291705P | 2005-03-17 | 2005-03-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GT200600116A true GT200600116A (es) | 2006-11-09 |
Family
ID=36617394
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GT200600116A GT200600116A (es) | 2005-03-17 | 2006-03-16 | Derivados de aril 1,4-pirazina sustituidos |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US20060211710A1 (es) |
| EP (1) | EP1871763A1 (es) |
| JP (1) | JP2008533124A (es) |
| KR (1) | KR20070113294A (es) |
| CN (1) | CN101160304A (es) |
| AP (1) | AP2007004174A0 (es) |
| AR (1) | AR056279A1 (es) |
| AU (1) | AU2006238976A1 (es) |
| BR (1) | BRPI0606284A2 (es) |
| CA (1) | CA2601600C (es) |
| CR (1) | CR9436A (es) |
| DO (1) | DOP2006000056A (es) |
| EA (1) | EA012874B1 (es) |
| GT (1) | GT200600116A (es) |
| IL (1) | IL185997A0 (es) |
| MA (1) | MA29336B1 (es) |
| MX (1) | MX2007011423A (es) |
| NL (1) | NL1031384C2 (es) |
| NO (1) | NO20075209L (es) |
| PE (1) | PE20061108A1 (es) |
| TN (1) | TNSN07355A1 (es) |
| TW (1) | TWI315670B (es) |
| UA (1) | UA86873C2 (es) |
| UY (1) | UY29418A1 (es) |
| WO (1) | WO2006114666A1 (es) |
| ZA (1) | ZA200707933B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0525068D0 (en) | 2005-12-08 | 2006-01-18 | Novartis Ag | Organic compounds |
| US8349852B2 (en) | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
| US8183371B2 (en) * | 2009-10-30 | 2012-05-22 | Janssen Pharmaceutica Nv | Pyrazines as delta opioid receptor modulators |
| WO2011092293A2 (en) | 2010-02-01 | 2011-08-04 | Novartis Ag | Cyclohexyl amide derivatives as crf receptor antagonists |
| EP2531510B1 (en) | 2010-02-01 | 2014-07-23 | Novartis AG | Pyrazolo[5,1b]oxazole derivatives as crf-1 receptor antagonists |
| US8835444B2 (en) | 2010-02-02 | 2014-09-16 | Novartis Ag | Cyclohexyl amide derivatives as CRF receptor antagonists |
| JP2022062287A (ja) * | 2019-02-27 | 2022-04-20 | 住友化学株式会社 | ピリジルピラジン化合物の製造方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5872136A (en) * | 1996-04-03 | 1999-02-16 | Merck & Co., Inc. | Arylheteroaryl inhibitors of farnesyl-protein transferase |
| US5883105A (en) * | 1996-04-03 | 1999-03-16 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US5880140A (en) * | 1996-04-03 | 1999-03-09 | Merck & Co., Inc. | Biheteroaryl inhibitors of farnesyl-protein transferase |
| PA8467401A1 (es) * | 1998-02-17 | 2000-09-29 | Pfizer Prod Inc | Procedimiento para tratar la insuficiencia cardiaca |
| AU770600B2 (en) * | 1999-10-07 | 2004-02-26 | Amgen, Inc. | Triazine kinase inhibitors |
| IL139197A0 (en) * | 1999-10-29 | 2001-11-25 | Pfizer Prod Inc | Use of corticotropin releasing factor antagonists and related compositions |
| AU783915B2 (en) * | 2000-02-16 | 2005-12-22 | Neurogen Corporation | Substituted arylpyrazines |
| AU2002343557A1 (en) * | 2001-11-21 | 2003-06-10 | Pharmacia And Upjohn Company | Substituted aryl 1,4-pyrazine derivatives |
| US6992087B2 (en) * | 2001-11-21 | 2006-01-31 | Pfizer Inc | Substituted aryl 1,4-pyrazine derivatives |
| WO2003091225A1 (en) * | 2002-04-26 | 2003-11-06 | Pharmacia & Upjohn Company | Substituted pyrazine derivatives |
| WO2004024719A1 (en) * | 2002-09-12 | 2004-03-25 | Pharmacia & Upjohn Company Llc | Substituted 1,4-pyrazine derivatives |
-
2006
- 2006-02-27 US US11/363,009 patent/US20060211710A1/en not_active Abandoned
- 2006-03-02 DO DO2006000056A patent/DOP2006000056A/es unknown
- 2006-03-06 BR BRPI0606284-9A patent/BRPI0606284A2/pt not_active IP Right Cessation
- 2006-03-06 AU AU2006238976A patent/AU2006238976A1/en not_active Abandoned
- 2006-03-06 CN CNA2006800128070A patent/CN101160304A/zh active Pending
- 2006-03-06 EA EA200701758A patent/EA012874B1/ru not_active IP Right Cessation
- 2006-03-06 EP EP06765409A patent/EP1871763A1/en not_active Withdrawn
- 2006-03-06 AP AP2007004174A patent/AP2007004174A0/xx unknown
- 2006-03-06 JP JP2008501437A patent/JP2008533124A/ja not_active Ceased
- 2006-03-06 CA CA2601600A patent/CA2601600C/en not_active Expired - Fee Related
- 2006-03-06 MX MX2007011423A patent/MX2007011423A/es not_active Application Discontinuation
- 2006-03-06 KR KR1020077023701A patent/KR20070113294A/ko not_active Ceased
- 2006-03-06 UA UAA200710557A patent/UA86873C2/ru unknown
- 2006-03-06 WO PCT/IB2006/000564 patent/WO2006114666A1/en not_active Ceased
- 2006-03-13 UY UY29418A patent/UY29418A1/es not_active Application Discontinuation
- 2006-03-15 PE PE2006000289A patent/PE20061108A1/es not_active Application Discontinuation
- 2006-03-15 AR ARP060100986A patent/AR056279A1/es unknown
- 2006-03-16 TW TW095108969A patent/TWI315670B/zh not_active IP Right Cessation
- 2006-03-16 GT GT200600116A patent/GT200600116A/es unknown
- 2006-03-16 NL NL1031384A patent/NL1031384C2/nl not_active IP Right Cessation
-
2007
- 2007-09-17 IL IL185997A patent/IL185997A0/en unknown
- 2007-09-17 ZA ZA200707933A patent/ZA200707933B/xx unknown
- 2007-09-17 TN TNP2007000355A patent/TNSN07355A1/fr unknown
- 2007-09-17 MA MA30226A patent/MA29336B1/fr unknown
- 2007-10-11 NO NO20075209A patent/NO20075209L/no not_active Application Discontinuation
- 2007-10-12 CR CR9436A patent/CR9436A/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006114666A8 (en) | 2008-04-03 |
| UY29418A1 (es) | 2006-10-31 |
| CA2601600C (en) | 2010-09-14 |
| PE20061108A1 (es) | 2006-10-13 |
| AP2007004174A0 (en) | 2007-10-31 |
| MA29336B1 (fr) | 2008-03-03 |
| CR9436A (es) | 2007-11-23 |
| EA200701758A1 (ru) | 2008-02-28 |
| NL1031384C2 (nl) | 2007-01-23 |
| UA86873C2 (en) | 2009-05-25 |
| AR056279A1 (es) | 2007-10-03 |
| BRPI0606284A2 (pt) | 2009-06-09 |
| ZA200707933B (en) | 2009-08-26 |
| AU2006238976A1 (en) | 2006-11-02 |
| IL185997A0 (en) | 2008-01-20 |
| NL1031384A1 (nl) | 2006-09-20 |
| KR20070113294A (ko) | 2007-11-28 |
| TWI315670B (en) | 2009-10-11 |
| TNSN07355A1 (fr) | 2008-12-31 |
| CN101160304A (zh) | 2008-04-09 |
| WO2006114666A1 (en) | 2006-11-02 |
| US20060211710A1 (en) | 2006-09-21 |
| TW200700067A (en) | 2007-01-01 |
| NO20075209L (no) | 2007-10-11 |
| DOP2006000056A (es) | 2006-08-30 |
| MX2007011423A (es) | 2007-10-12 |
| JP2008533124A (ja) | 2008-08-21 |
| EA012874B1 (ru) | 2009-12-30 |
| CA2601600A1 (en) | 2006-11-02 |
| EP1871763A1 (en) | 2008-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GT200500101A (es) | Compuestos de metil-aril o heteroaril-amida sustituida | |
| GT200400013A (es) | Compuestos de pirazolotriazina y usos de los mismos | |
| DOP2009000126A (es) | Antagonistas de receptor de orexina de diazepan sustituído | |
| GT200400173A (es) | Compuestos de aril o heteroaril amida | |
| GT200200073A (es) | Derivados de dihidro-benzo (b) (1,4) diazepin-2-ona | |
| GT200500185A (es) | Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos | |
| GT200600306A (es) | Inhibidores de glutamato agrecanasa | |
| CL2008003787A1 (es) | Compuestos derivados de heteroarilo, antagonistas del receptor de orexina; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos del sueno, trastornos psiquiatricos, neurologicos, ansiedad, depresion, esquizofrenia, alzheimer, parkinson, entre otras. | |
| NO20092762L (no) | 2-aza-bicyklo[3.1.0]heksanderivater | |
| GT200500272A (es) | 2-anilinopirimidinas sustituidas como inhibidores de la quinasa del ciclo celular o del receptor de la tirosina quinasa, su preparacion y su uso como medicamentos | |
| GT200200072A (es) | Derivados de dihidro-benzo (b) (1,4)-diazepin-2-ona | |
| GT200600030A (es) | 2-fenil-indoles como antagonistas del receptor de la prostaglandina d2 | |
| ATE524466T1 (de) | 3-azabicycloä3.3.0üoktanverbindungen | |
| ECSP11011019A (es) | Antagonistas del receptor de orexina de isonicotinamida | |
| ECSP088210A (es) | Bencimidazoles sustituidos y métodos de preparación | |
| GT200600184A (es) | Derivados de purina | |
| GT200200090A (es) | Derivados de quinolina | |
| GT200500226A (es) | Compuestos de aminoheteroarilo sustituidos con pirazol como inhibidores de proteina quinasa | |
| GT200600107A (es) | Compuestos de n-sulfonilaminofeniletil-2-fenoxiacetamida sustituidos | |
| GT200600128A (es) | Derivados de ciclopentapiridina y tetrahidroquinolina | |
| GT200500218A (es) | Derivados de triazolopiridinilsulfanilo como inhibidores de quinasa map p38 | |
| GT200200269A (es) | Derivados de 7-amino-benzotiazol | |
| GT200500292A (es) | Derivados de 2-amido-4-feniltiazol, su preparacion y su aplicacion en terapeutica | |
| GT200300033A (es) | Derivados de nicotinamida utiles como inhibidores de pde4 | |
| GT200600155A (es) | Compuestos utiles en terapia |